Simcere Pharmaceutical Group Ltd
HKEX:2096
Intrinsic Value
Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one
Simcere Pharmaceutical Group Ltd
stock under the Base Case scenario is
12.56
HKD.
Compared to the current market price of 5.24 HKD,
Simcere Pharmaceutical Group Ltd
is
Undervalued by 58%.
Simcere Pharmaceutical Group Ltd's market capitalization is 13.8B HKD.
Simcere Pharmaceutical Group Ltd stock price is 5.24 HKD.
Simcere Pharmaceutical Group Ltd stock price (5.24 HKD) is 58% less than its Intrinsic Value (12.56 HKD).
Simcere Pharmaceutical Group Ltd stock price (5.24 HKD) is 45% less than its DCF Value (9.59 HKD). Open DCF Valuation
Simcere Pharmaceutical Group Ltd stock price (5.24 HKD) is 66% less than its Relative Value (15.53 HKD). Open Relative Valuation
Simcere Pharmaceutical Group Ltd has upside potential of 85% compared to the average analyst price target.
Open Wall St Estimates
Simcere Pharmaceutical Group Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 10%.
Simcere Pharmaceutical Group Ltd has negative Free Cash Flow for the last twelve months.
Simcere Pharmaceutical Group Ltd's Revenue has grown by 4% over the past 12 months.
Simcere Pharmaceutical Group Ltd has positive Operating Income for the last twelve months.
Simcere Pharmaceutical Group Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
Simcere Pharmaceutical Group Ltd's ROE (Return on Equity) has decreased in the last 3 years from 13% to 10%.
Simcere Pharmaceutical Group Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 6% to 8%.
Simcere Pharmaceutical Group Ltd has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
Simcere Pharmaceutical Group Ltd's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
Simcere Pharmaceutical Group Ltd's Revenue has been growing by 14% per year for the last 3 years.
Simcere Pharmaceutical Group Ltd has positive Net Income for the last twelve months.
Simcere Pharmaceutical Group Ltd has positive three-year average ROE (Return on Equity): 21%. The company is efficient at transforming stockholders' equity into net income.
Simcere Pharmaceutical Group Ltd's short-term assets (6B CNY) exceed its short-term liabilties (3B CNY).
Simcere Pharmaceutical Group Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (1B CNY).
Simcere Pharmaceutical Group Ltd has positive Gross Profit for the last twelve months.
Simcere Pharmaceutical Group Ltd's long-term assets (11B CNY) exceed its long-term liabilties (4B CNY).
Simcere Pharmaceutical Group Ltd's D/E (Debt to Equity) is very low and is equal to 0.15.
Simcere Pharmaceutical Group Ltd's Altman Z-Score is very high and is equal to 4.46.
Valuation Backtest
Simcere Pharmaceutical Group Ltd
Run backtest to discover the historical profit from buying and selling
Simcere Pharmaceutical Group Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Simcere Pharmaceutical Group Ltd
Balance Sheet Decomposition
Simcere Pharmaceutical Group Ltd
| Current Assets | 5.6B |
| Cash & Short-Term Investments | 2B |
| Receivables | 2.6B |
| Other Current Assets | 976m |
| Non-Current Assets | 5.2B |
| Long-Term Investments | 1.6B |
| PP&E | 2.2B |
| Intangibles | 858.3m |
| Other Non-Current Assets | 606.3m |
| Current Liabilities | 2.7B |
| Accounts Payable | 317.2m |
| Short-Term Debt | 762.4m |
| Other Current Liabilities | 1.6B |
| Non-Current Liabilities | 945m |
| Long-Term Debt | 334.2m |
| Other Non-Current Liabilities | 610.8m |
Earnings Waterfall
Simcere Pharmaceutical Group Ltd
|
Revenue
|
6.6B
CNY
|
|
Cost of Revenue
|
-1.6B
CNY
|
|
Gross Profit
|
5B
CNY
|
|
Operating Expenses
|
-4.3B
CNY
|
|
Operating Income
|
697.6m
CNY
|
|
Other Expenses
|
17.2m
CNY
|
|
Net Income
|
714.8m
CNY
|
Free Cash Flow Analysis
Simcere Pharmaceutical Group Ltd
Profitability Score
Profitability Due Diligence
Simcere Pharmaceutical Group Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Simcere Pharmaceutical Group Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Simcere Pharmaceutical Group Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Simcere Pharmaceutical Group Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Simcere Pharmaceutical Group Ltd
According to Wall Street analysts, the average 1-year price target for
Simcere Pharmaceutical Group Ltd
is 9.71 HKD
with a low forecast of 7.62 HKD and a high forecast of 13.87 HKD.
Shareholder Return
Price
Simcere Pharmaceutical Group Ltd
| Average Annual Return | 3.09% |
| Standard Deviation of Annual Returns | 23.57% |
| Max Drawdown | -63% |
| Market Capitalization | 13.8B HKD |
| Shares Outstanding | 2 609 760 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Simcere Pharmaceutical Group Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2020-10-27. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces innovative drugs, such as Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions.
Contact
IPO
Employees
Officers
The intrinsic value of one
Simcere Pharmaceutical Group Ltd
stock under the Base Case scenario is
12.56
HKD.
Compared to the current market price of 5.24 HKD,
Simcere Pharmaceutical Group Ltd
is
Undervalued by 58%.
You don't have any saved screeners yet
